A phase II study of Sutent (SU11248) [sunitinib] as second line treatment in pleural mesothelioma after first line treatment with a platinum and antimetabolite
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2008
At a glance
- Drugs Sunitinib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 09 Oct 2007 New trial record.